Enclosed is the transcript of the conference call held on 01.08.2026.

6th August, 2026 BSE Limited National Stock Exchange of India Limited Phiroze JeeJeebhoy Towers, Exchange Plaza, Plot no. C/1, Dalal Street, G Block, Bandra-Kurla Complex Fort, Mumbai – 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543318 Trading Symbol: CLEAN Subject: Transcript of conference call on the Company’s Q1 FY26-27 Earnings. Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Dear Sir/Madam Further to our letter dated 21st July, 2026 and in terms of Regulation 30 read with Schedule III - Part A to the Listing Regulations, please find enclosed herewith the transcript of conference call on the Company’s Q1 FY26-27 Earnings held on Saturday, 1st August, 2026. You are requested to take the same on record. Thanking You. For Clean Science and Technology Limited Ruchita Vij Company Secretary & Compliance Officer Encl: as above “Clean Science and Technology Limited Q1 FY27 Earnings Conference Call” August 01, 2026 MANAGEMENT: MR. SIDDHARTH SIKCHI – MANAGING DIRECTOR AND PROMOTER – CLEAN SCIENCE AND TECHNOLOGY LIMITED MR. SANJAY PARNERKAR – CHIEF FINANCIAL OFFICER – CLEAN SCIENCE AND TECHNOLOGY LIMITED MR. PRATIK BORA – PRESIDENT, COMMERCIAL – CLEAN SCIENCE AND TECHNOLOGY LIMITED Page 1 of 17 Clean Science and Technology Limited August 01, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY27 Earnings Conference Call of Clean Science and Technology Limited. We have with us on the call Siddharth Sikchi, Managing Director and Promoter; Sanjay Parnerkar, CFO; and Pratik Bora, President, Commercial. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch- tone phone. I now hand the conference over to Mr. Siddharth Sikchi for opening remarks. Thank you, and over to you, Mr. Siddharth Sikchi. Siddharth Sikchi: Thank you so much, Iqra. Good evening, everybody. Thank you so much for attending the call on a Saturday evening. So let me start by welcoming everyone and a warm welcome for the quarter 1 FY27 earnings call of the company, and I thank you for joining the call. Let me first speak on the business environment. The quarter performance shall be viewed in backdrop of geopolitical headwinds impacting raw material supply chain and its cost. Non- availability of shipping vessels impacted timely export of goods, leading to supply side challenges. Further, the raw material costs in China were not impacted as much as they were compared to India. Despite external challenges during the quarter, Clean Science reported a steady performance during the quarter. The company was able to improve revenue, maintain operational stability, and continue progress on its value-creating initiatives. We are also pleased to report our highest ever consolidated sales in company's history, reaching approximately INR264 crores during the quarter. Let me speak on the standalone business performance. On a sequential basis, the revenue improved by 5% to INR 203 crores, largely due to increase in realization in all the products. The EBITDA and the PAT margins are at 43% and 36%, translating into an EBITDA of INR87 crores and PAT of INR 73 crores. The Q4 FY26 EBITDA and PAT after adjusting the one-off operating expense transactions is roughly INR 83 crores and INR 53 crores, respectively. Thereby, the current quarter EBITDA and PAT reflected a growth of 5% and 37%, respectively. The Q-on-Q increase in revenue was primarily led by improved realization in all the segments. Speaking on Y-o-Y comparison, the sales were moderated by 6% during the quarter. The revenue moderation was primarily led by decrease in sales volume, which was on account of supply side headwinds as mentioned earlier. The demand environment continues to be steady. On consolidated business performance, the HALS scaleup continues to drive operating leverage and sustainable profit improvement. HALS is now 22% of our sales, and we have been able to Page 2 of 17 Clean Science and Technology Limited August 01, 2026 derisk our reliance on the top 4 legacy products by moderating their share from 85% in Q4 FY23 to 60% this quarter. Another important point was that CFCL reached an important milestone by becoming operationally self-sustaining. Having fully recovered its operating expenses, we now shift from investing phase to monetizing phase. Our first year of HALS sales were entirely domestic. In contrast, the current quarter reflects a much more diversified geographical mix with exports contributing nearly 50% of the HALS sales. On a sequential basis, the consolidated revenues grew by 7% to INR 264 crores. EBITDA and PAT are 37% and 28%, respectively, which stands at INR 96 crores and INR 73 crores, respectively. On a Y-o-Y basis, the revenue increased by 10% during the quarter, and the increase in revenue is primarily led by consistent scale-up of our HALS business. Hence, the sales profile looks like Performance, Pharma and FMCG, respectively, 83%, 10% and 7%, respectively. I would like to take a minute to discuss the key business development which happened during the quarter. Point 1, we entered into a strategic collaboration with our Swiss partner called as Geneus Chem. This represents an important step in the next phase of our HALS journey. This will provide Clean Science an entry into differentiated advanced grade of HALS chemistry that are technology-intensive, value-added and aligned and evolving global customer requirements. Taken together, these developments reinforce our confidence that HALS platform can evolve into a much stronger growth driver for the company over the coming years. With expanding customer acceptance, improving export penetration and a richer product basket, we believe that the platform is steadily moving towards more meaningful scale, stronger margins and greater strategic importance within the company's portfolio. The stabilization of the hydroquinone and catechol plant has been largely completed and our operations are now progressing well. We have received the necessary customers' approval and are ramping up for commercial supplies. As the production scales up, we expect a gradual increase in revenue in the coming quarters. On a capex update, the Performance Chemical 2 will get commercialized by quarter 3 FY27. And during the quarter, capital infusion in the subsidiary was approximately INR100 crores with this total investment in the subsidiary stands at approximately INR850 crores. I think that's all from my side, and I'm open for any questions-and-answers. Moderator: Thank you very much. We will now begin the question-and-answer session. The first question is from the line of Sanjesh from ICICI Securities. Page 3 of 17 Clean Science and Technology Limited August 01, 2026 Sanjesh: Got a couple of questions. First on the HALS, what was the volume this quarter, because the consol minus subsidiary, it shows we have grown close to 170%. So what was the mix of volume and pricing? And how much was the contribution of the products beyond 701 and 770? Siddharth Sikchi: In terms of price realization, Sanjesh, the product mix has improved. From 770, 622, we have now moved to the higher grades. So I think the average prices have moved from 440-odd to 550. So this is in terms of price realization. And in terms of volume... Pratik Bora: Sanjesh, volumes are in the range of 1,000 tons, and the product mix has significantly improved to the higher grades of HALS, meaning, I mean, last quarter where almost 50% of contribution came in from HALS 770, this quarter it has come down to 35-odd percent. And hence, the gross margins have improved on the subsidiary level. Sanjesh: Got it. Got it. Siddharth, we were looking at, what, close to 3,000 metric tons for HALS this year. You think you ca [Showing first 8,000 characters — download PDF for full document]